# Aarti Pharmalabs (NSE: AARTIPHARM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AARTIPHARM · Pivot · prices to 21 Oct 2026

Aarti Pharmalabs (NSE: AARTIPHARM) closed at ₹838.90 on 21 Oct 2026. With a market capitalisation of ₹7,572 Cr, it ranks 641st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 43.4× trailing earnings, against a return on equity of 13.7% in FY25. Over the past year the share price has risen 0.3%. Its 52-week range is ₹585.00 (30 Mar 2026) to ₹1,002.40 (30 Sep 2026); the last close is 16.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹583 Cr (+3.3% year on year) and net profit ₹56 Cr (−37.1%), on a consolidated basis. Promoters held 42.86% of the company as of 30 Jun 2026; 11.08% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹838.90 |
| Market cap | ₹7,572 Cr |
| P/E (trailing) | 43.4 |
| ROE | 13.7% (FY25) |
| ROCE | 17.2% (FY25) |
| Debt to equity | 0.2 |
| 52-week high | ₹1,002.40 (30 Sep 2026) |
| 52-week low | ₹585.00 (30 Mar 2026) |
| 1-year return | +0.3% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹583 Cr | +3.3% | ₹56 Cr | −37.1% | ₹6.74 |
| Q3 FY26 | ₹432 Cr | −19.6% | ₹43 Cr | −41.8% | ₹5.29 |
| Q2 FY26 | ₹418 Cr | −8.7% | ₹29 Cr | −47.7% | ₹3.08 |
| Q1 FY26 | ₹386 Cr | −30.5% | ₹51 Cr | −7.5% | ₹5.46 |
| Q4 FY25 | ₹564 Cr | +11.5% | ₹88 Cr | +35.4% | ₹9.75 |
| Q3 FY25 | ₹538 Cr | +19.9% | ₹74 Cr | +40.2% | ₹8.16 |
| Q2 FY25 | ₹458 Cr | +4.1% | ₹55 Cr | +5.4% | ₹6.03 |
| Q1 FY25 | ₹555 Cr | +21.2% | ₹55 Cr | +17.8% | ₹6.12 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,115 Cr | ₹272 Cr |
| FY24 | ₹1,853 Cr | ₹217 Cr |
| FY23 | ₹1,945 Cr | ₹193 Cr |
| FY22 | ₹1,200 Cr | ₹122 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 42.86%
- Foreign institutions: 8.17%
- Domestic institutions: 7.22%
- Non-institutions: 41.74%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Healthcare Global Enterprises](https://app.pivotnow.in/stock/HCG) | ₹570.00 | ₹8,510 Cr | — | — |
| [Suven Life Sciences](https://app.pivotnow.in/stock/SUVEN) | ₹290.50 | ₹8,208 Cr | — | — |
| [Sanofi Consumer Healthcare India](https://app.pivotnow.in/stock/SANOFICONR) | ₹3,473.40 | ₹7,999 Cr | 31 | — |
| [Thyrocare Technologies](https://app.pivotnow.in/stock/THYROCARE) | ₹469.95 | ₹7,480 Cr | 46.1 | — |
| [Supriya Lifescience](https://app.pivotnow.in/stock/SUPRIYA) | ₹872.50 | ₹7,022 Cr | 33.6 | — |
| [Morepen Laboratories](https://app.pivotnow.in/stock/MOREPENLAB) | ₹125.70 | ₹6,888 Cr | 72.7 | — |

## Questions and answers

### What is the share price of Aarti Pharmalabs today?

Aarti Pharmalabs (NSE: AARTIPHARM) last closed at ₹838.90 on 21 Oct 2026. Its 52-week high is ₹1,002.40 and its 52-week low is ₹585.00.

### What is the market cap of Aarti Pharmalabs?

Aarti Pharmalabs' market capitalisation is ₹7,572 Cr (₹7,572 Cr) at the 19 Oct 2026 close, ranking 641st among the NSE companies Pivot tracks.

### What is the P/E ratio of Aarti Pharmalabs?

Aarti Pharmalabs trades at a trailing P/E of 43.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 46.1.

### What is the ROE and ROCE of Aarti Pharmalabs?

Return on equity was 13.7% in FY25 and return on capital employed was 17.2% in FY25 (consolidated figures).

### Is Aarti Pharmalabs a debt-free company?

No. Aarti Pharmalabs' debt-to-equity ratio was 0.2 in FY25, with total debt of ₹104 Cr.

### What were Aarti Pharmalabs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Aarti Pharmalabs reported revenue of ₹583 Cr, +3.3% year on year, and net profit of ₹56 Cr, −37.1% year on year.

### How has Aarti Pharmalabs stock performed over the last year?

Aarti Pharmalabs' share price has risen 0.3% over the past year, +19.3% over three months and +0.7% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Aarti Pharmalabs?

As of 30 Jun 2026: promoters 42.86%, foreign institutions 8.17%, domestic institutions 7.22%, non-institutions 41.74%. 11.08% of promoter shares were pledged.

### Who are Aarti Pharmalabs' competitors?

The listed Pharma & Healthcare companies closest to Aarti Pharmalabs by market cap are Healthcare Global Enterprises, Suven Life Sciences, Sanofi Consumer Healthcare India, Thyrocare Technologies, Supriya Lifescience and Morepen Laboratories.

### Is Aarti Pharmalabs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aarti Pharmalabs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AARTIPHARM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.